Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
A new phenomenon was discovered where increased pressure leads to a sudden burst of rapid and coordinated cellular motion, spraying outwards from the tumour. This fluid-like pushing mechanism can kill cancer cells but also enables them to survive and multiply in new environments.
Researchers identify two genes, GLI1 and Notch1, responsible for aggressive growth and spread of triple negative breast cancers in African American women. A combination approach using inhibitors and chemotherapy agents significantly inhibits tumor growth and metastasis.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
Researchers at Karolinska Institutet have found a way to stabilize the cancer-suppressing protein p53 by adding a spider silk protein, creating a more potent variant. This discovery has potential as an approach for cancer therapy.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
Researchers at UNIGE find that near-death experience in primary tumors triggers pro-metastatic states in cells, leading to metastasis. These 'PAME' cells reprogram themselves and trigger a cytokine storm, forming new tumors.
Researchers at Moffitt Cancer Center have developed patient-derived cells that can be used to study leptomeningeal disease, a rare complication of cancer. The cells provide a new opportunity for scientists to understand the disease and identify potential therapeutics.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
Moffitt researchers have identified key genomic alterations and potential therapeutic targets in transformed cutaneous T-cell lymphoma. The study, which analyzed 56 patient samples, found high tumor mutation burden and UV mutation signatures associated with survival outcomes. The research also uncovered novel therapeutic vulnerabilitie...
Researchers have found that statins can inhibit the formation of tumors and metastases in animals with increased MACC1 expression. A study analyzing data from over 300,000 patients prescribed statins also showed a correlation between statin use and reduced cancer incidence.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
Researchers at the University of Helsinki found that a cellular stress state predicts a poor chemotherapy response in ovarian cancer patients. High-stress tumours with an inflammatory microenvironment may resist chemotherapy, making combination therapies a potential solution.
Researchers investigated COVID-19 mortality in adult cancer patients, finding that systemic treatments and comorbidities played a role in increased risk. The study analyzed 2,500 patients and identified specific tumor subtypes associated with higher mortality rates.
Scientists have developed a new therapy called CINDELA, which employs CRISPR-Cas9 to kill cancer cells while leaving normal tissues intact. The treatment targets specific mutations found in cancer cells and induces cell death through DNA double-strand breaks.
A Swiss-French team has identified a mechanism that could lead to the development of new therapies for acute myeloid leukaemia, a particularly dangerous form of cancer. The selective activation of AMPK triggers apoptosis in tumour cells by initiating the cell's stress response.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
Researchers have discovered that the tumor suppressor protein pVHL degrades SMAD3, inhibiting the TGF-β signaling pathway and suppressing tumour cell growth. This finding opens up new opportunities for developing cancer therapies by regulating pVHL activity.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
Researchers have designed a nanoparticle system that can deliver fluorescent dyes to diagnose and treat pancreatic cancer tumors. The system overcomes the challenge of reaching cells deep within dense tumor masses, enabling detailed images of tumor structures and potentially targeted therapies.
Researchers found that macrophages feed on lactic acid produced by cancer cells, paralyzing killer immune cells and weakening tumour immunity. This discovery highlights the need to curb lactic acid production in tumours to improve immunotherapy outcomes.
Researchers at Northwestern University have developed a novel microfluidic device that can efficiently harvest and sort tumor-eating immune cells from tumors. This technology has shown dramatic results in shrinking tumors in mice compared to traditional methods.
Researchers found that hyaluronic acid is not only present in pancreatic tumors but also serves as a nutrient source for cancer cells. This discovery indicates potential new treatments for pancreatic cancer by targeting the sugar scavenging pathway.
Researchers used optical imaging to study the metabolic interactions between pancreatic cancer cells and surrounding non-cancer cells. They found that cancer cells can hijack the metabolic activity of these non-cancer cells to fuel tumor growth. This discovery could lead to new therapies targeting the tumor microenvironment.
Melanoma cells release small packages containing the protein NGFR, which primes nearby lymph nodes to form new vessels and encourage cancer spread. This process, called lymphangiogenesis, may help doctors determine which patients need more aggressive treatment.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Researchers at Karolinska Institutet have identified a specific connection between a protein and an lncRNA molecule that can help decrease fat depots in tumor cells, leading to cell division cessation and cancer cell death. The study contributes to increased knowledge of liver cancer diagnosis and future treatments.
A study reveals how CSDE1 coordinates skin cell senescence, slowing down cellular function without causing death. This leads to the formation of a firewall against cancer, suppressing tumor growth.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
Researchers at Moffitt Cancer Center have identified the molecular and cellular mechanisms that control the formation of tertiary lymphoid structures within tumors. These structures contain immune cells and can promote anti-tumor activity when Tfh cells are introduced, leading to improved outcomes in patients with certain types of cancer.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers have revealed mechanisms by which polyps develop into colorectal cancer, setting the stage for improved surveillance utilizing precision medicine. The study found that serrated polyps derive from metaplasia, an abnormal change of cells into non-native tissue.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers have discovered a nanoparticle therapeutic that enhances cancer immunotherapy and treats malignant pleural effusion. The treatment targets the immune system to recognize and eliminate cancer cells, improving survival rates and quality of life for patients.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
Researchers analyzed 140 neuroblastoma samples to understand the genetic changes associated with the disease. They found that mutations can disappear and reappear, occurring in distinct sections or individual cells, making targeted therapy less effective.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
Alphataxin, a small-molecule drug, has been shown to significantly suppress tumor growth in mouse models of kidney cancer, including those with lung metastasis. The treatment also increased the formation of CD4+ T cells, which is essential for the immune system's ability to kill tumor cells.
Researchers used imaging mass cytometry to analyze protein expression and cell location in tumor samples. High density of antigen-presenting cells with high PD-L1 and IDO expression was associated with higher pathological complete response rate in patients treated with atezolizumab plus chemotherapy.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.
Researchers have developed new preclinical models to understand gastric cancer development and spread. Using these models, they identified Lgr5-expressing tumour cells as responsible for driving gastric cancer growth and spread, establishing them as a potential therapeutic target.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
Researchers at Massachusetts General Hospital have developed a method to detect early signs of tumor cell death using MRI and AI, allowing for non-invasive monitoring of cancer treatment. This approach has shown promise in detecting treatment-responsive regions in mouse brain tumors and healthy human brains.
Scientists have identified a cascade of four proteins that activate the cancer-causing protein ∆Np63α. By inhibiting these proteins, cancer stem cells can be controlled, and tumor growth slowed. This breakthrough offers new therapeutic options for squamous cell carcinoma.
A study found that the MYCN protein creates conflicts between DNA replication and transcription in cancer cells, leading to increased division rates and potential damage. The researchers hope to develop therapies by disrupting the cooperation between MYCN and a molecule called BRCA1.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
Researchers at Saarland University have discovered that the lipid and cholesterol metabolism of immune cells collaborating with tumour cells is severely compromised compared to tumour tissue. This finding suggests a possible explanation for why cholesterol-lowering drugs are ineffective against non-small-cell lung carcinoma.
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
Researchers identified a subset of dendritic cells that can cloak themselves in tumor proteins and trigger a strong T cell response. Stimulating these dendritic cells may enhance the effectiveness of cancer immunotherapy by slowing the growth of melanoma and colon tumors.
Researchers at UVA Cancer Center discovered how a common gene mutation disrupts cells' ability to suppress tumors. The mutation in the UTX gene forms tiny droplets that help prevent tumor formation.
A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.
New study suggests inhibiting Shp2 in tumor cells may boost tumor growth and survival, complicating its use as a potential cancer therapy for HCC.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.